Sangamo showcases progress in our pre-clinical programs at ASGCT.
Click here to view
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
LinkedIn
Twitter
ESGCT 2022
Preliminary results of STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease and long term follow up
November 1st, 2022
Engineering of Allogeneic Regulatory T Cells Expressing a Chimeric Antigen Receptor (Allo-CAR-Tregs) Using Zinc Finger Nuclease/AAV6-Mediated Editing
November 1st, 2022
Engineering of Factor IX-secreting B cells using ZF-Nuclease / AAV6 editing technology in a GMP-compatible medium
November 1st, 2022